UCB fell one place to eighth on the 2026 Global Pharmaceutical Innovation Index and 10 places to 28th on the Invention Index. Its Innovation ranking reflects strong commercial and clinical execution, underpinned by a focused specialty strategy. Revenue growth remains robust, driven by continued momentum from its key growth drivers.

The most significant regulatory milestone was the FDA approval of Kygevvi (doxecitine and doxribtimine), the first and only treatment for thymidine kinase 2 deficiency, representing a meaningful advance in a rare pediatric disease. UCB also strengthened its neurology portfolio, with approval for at-home self-administration of Rystiggo (rozanolixizumab) and further expansion of Zilbrysq (zilucoplan) in generalized myasthenia gravis.